CD274 and non-small cell lung carcinoma: However, given the desirability of having therapeutic alternatives in this subgroup of advanced and metastasic NSCLC patients, other treatments such as atezolizumab, a humanised IgG1 monoclonal antibody anti-PD-L1, has demonstrated significant clinical benefit [22].